PTC Therapeutics
PTCT
157 hedge funds and large institutions have $880M invested in PTC Therapeutics in 2015 Q3 according to their latest regulatory filings, with 38 funds opening new positions, 64 increasing their positions, 44 reducing their positions, and 35 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 44
29% more call options, than puts
Call options by funds: $133M | Put options by funds: $103M
1% more funds holding
Funds holding: 155 → 157 (+2)
9% more first-time investments, than exits
New positions opened: 38 | Existing positions closed: 35
44% less capital invested
Capital invested by funds: $1.57B → $880M (-$694M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$28.5M |
| 2 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
+$22.3M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$13.6M |
| 4 |
Barclays
London,
United Kingdom
|
+$12.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$52.4M |
| 2 |
Westfield Capital Management
Boston,
Massachusetts
|
-$52M |
| 3 |
HCM
Highbridge Capital Management
New York
|
-$12.1M |
| 4 |
O
OppenheimerFunds
New York
|
-$12M |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.84M |
PTCT Hedge Fund Activity: Q3 2015 in Review
157 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q3 2015, worth a combined $880M — down 44% from $1.57B a quarter earlier.
Buyers outnumbered sellers: 38 funds opened new PTCT positions and 35 closed out — a net gain of 3 holders — while 64 added to existing stakes and 44 trimmed.
The largest buyer was Jennison Associates, opening a new position worth an estimated $28.5M. The largest seller was Fidelity Investments, cutting an estimated $52.4M.
- 157 institutional investors held PTC Therapeutics (PTCT) as of Q3 2015, up from 155 in Q2 2015.
- Funds reported $880M of PTC Therapeutics stock for Q3 2015, down 44% quarter-over-quarter.
- 38 funds opened new PTC Therapeutics positions in Q3 2015 and 35 closed out, a net change of +3 holders.
- The largest PTC Therapeutics buyer in Q3 2015 was Jennison Associates, an estimated $28.5M added.
- The largest PTC Therapeutics seller in Q3 2015 was Fidelity Investments, an estimated $52.4M sold.
Based on aggregated 13F filings for Q3 2015.